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Objective: To estimate health status utility (preference) weights for hereditary angioedema 
(HAE) during an attack and between attacks using data from the Hereditary Angioedema Bur-
den of Illness Study in Europe (HAE-BOIS-Europe) survey. Utility measures quantitatively 
describe the net impact of a condition on a patient’s life; a score of 0.0 reflects death and 1.0 
reflects full health.
Study design and methods: The HAE-BOIS-Europe was a cross-sectional survey con-
ducted in Spain, Germany, and Denmark to assess the real-world experience of HAE from the 
patient perspective. Survey items that overlapped conceptually with the EuroQol 5-Dimensions 
(EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) 
were manually crosswalked to the corresponding UK population-based EQ-5D utility weights. 
EQ-5D utilities were computed for each respondent in the HAE-BOIS-Europe survey for acute 
attacks and between attacks.
Results: Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey 
items and thus allowed for computation of EQ-5D-based utilities. The mean utilities for an 
HAE attack and between attacks were 0.44 and 0.72, respectively. Utilities for an acute attack 
were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for 
moderate pain, and 0.08 for severe pain). There were no significant differences across countries. 
Mean utilities derived from the study approach compare sensibly with other disease states for 
both acute attacks and between attacks.
Conclusion: The impacts of HAE translate into substantial health status disutilities associated 
with acute attacks as well as between attacks, documenting that the detrimental effects of HAE 
are meaningful from the patient perspective. Results were consistent across countries with regard 
to pain severity and in comparison to similar disease states. The results can be used to raise 
awareness of HAE as a serious disease with wide-ranging personal and social impacts.
Keywords: hereditary angioedema, health-related quality of life, burden of illness, EQ-5D
Introduction
Hereditary angioedema (HAE) is a rare genetic disorder caused by C1 inhibitor (C1 
INH) deficiency, resulting in recurrent subcutaneous or submucosal edema.1–4 HAE is a 
lifelong disease with symptoms often beginning in early childhood1,5 and diagnosis may 
be delayed for 10 years.3,5,6 Patients with HAE may experience disfiguring, functionally 
disabling, painful, and even life-threatening edema of the face, extremities, upper air-
way, gastrointestinal tract, and urogenital region.2,7,8 Attack frequency may range from 
rarely to once every 3 days, and the disease presentation may vary throughout a patient’s 
life.2,9 Symptoms typically last 1–4 days and patients may be unable to engage in nor-
mal social activities for 20–100 days per year.10 The unpredictable nature and potential 
seriousness of frequent angioedema attacks may put a strain on the patient and his/her 
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family. Recently published data suggest that patients with 
HAE experience greater interference in their education and 
careers due to work and school absenteeism and productivity 
impairment during and between attacks.11 The prevalence of 
HAE is approximately estimated at 1:50,000.10,12
Disease management strategies include treatment of 
acute attacks, preprocedure attack prophylaxis, and long-
term prophylaxis to minimize the frequency and severity 
of attacks.13,14 Treatment options mostly consist of plasma-
derived or recombinant C1 INH concentrates and a B2 bra-
dykinin receptor antagonist for the treatment of acute attacks. 
Long-term prophylaxis options involve attenuated androgens 
and a nanofiltered C1 INH (human). Plasma-derived C1 INHs 
have been recommended for preprocedure prophylaxis.15
The Hereditary Angioedema Burden of Illness Study 
in Europe (HAE-BOIS-Europe) survey was undertaken to 
collect patient-reported European data to address significant 
gaps in the literature with respect to the humanistic and 
socioeconomic burden of HAE from the patient perspective, 
focusing on Spain, Germany, and Denmark, as described by 
Bygum et al16 and Caballero et al.17
Despite the increasing wealth of information about the 
disease, the broader consequences of HAE on patients’ lives 
are yet to be fully understood. Within this context, the objec-
tive of this study was to produce estimates of utility values 
associated with acute attacks as well as between attacks based 
on existing patient-reported data. Utility, or preference, mea-
sures allow the net impact of the effects of a condition to be 
captured quantitatively.18 For such measures, a score of 0.0 
reflects death and a score of 1.0 reflects full health; changes of 
0.05 are generally considered meaningful to the patient.19 The 
utility weights are often used to quality-adjust life expectancy 
in cost–utility evaluations of medical interventions.20,21
Given the rarity of HAE and the high cost of treatment,15,22 
utility values could be an important influential factor in policy 
decision models and cost–utility studies of HAE treatments. 
Furthermore, due to the rarity and episodic nature of the 
condition, it may be particularly challenging to accurately 
estimate the clinical and humanistic impact of HAE in daily 
practice. Utilities can be used to raise awareness of the seri-
ousness of HAE, provide a basis for comparison with other 
chronic diseases, and provide evidence of the need for more 
effective treatments.
Patients and methods
The HAE-BOIS-Europe survey was conducted between 
May and December 2011. The two study components were: 
1) a one-time web- or paper-based survey on the humanistic 
and socioeconomic burden of HAE, which included questions 
regarding experience related to the last HAE attack as well as 
between attacks11,16,17 and 2) open-ended patient interviews 
(N=30 [n=10 per country]).23 Interview participants were 
selected from clinical practice centers of excellence, and sur-
vey participants were recruited systematically from clinical 
practice as well as from patient associations. Participants 
were at least 12 years of age with HAE type I or type II. 
The study was reviewed and approved by institutional 
review boards per local requirements. Interview participants 
provided verbal informed consent before the interview, 
and survey participants provided written informed consent 
electronically or on paper before beginning the survey. For 
participants under the age of 18 years, parental consent was 
obtained in addition to the child’s assent. Means of patient 
recruitment, population, and attack characteristics, including 
use of acute attack treatment and long-term prophylaxis, have 
been previously published.11,16,17
An approach for obtaining utility weights for HAE attacks 
as well as between attacks was designed by reviewing the 
HAE-BOIS-Europe survey to identify items that most closely 
matched the EuroQol 5-Dimensions (EQ-5D) conceptually. 
Separate items were identified for the most recent HAE 
attacks and between attacks. The EQ-5D, one of the most 
common utility measures, is a 5-item instrument measuring 
current pain/discomfort, mobility, self-care, usual activities, 
and anxiety/depression.24,25 Each domain has three levels 
of severity (no problems, some or moderate problems, and 
extreme problems).
Response options for the selected HAE-BOIS-Europe 
survey items were manually crosswalked to the respective 
EQ-5D domain severity levels based on the judgment of 
four clinical expert investigators. For two items, data from 
the qualitative interviews also provided insight for this. 
Specifically, the qualitative interviews included obtaining 
feedback on two HAE-BOIS-Europe survey items. Patients 
were asked to identify a number on a 0–10 scale reflecting 
their anxiety about future attacks and the impact of the last 
attack on their ability to perform daily activities. Patients 
were then asked why they chose this number. Evaluation of 
the results determined the ranges within the 0–10 response 
scales that were assigned to the respective EQ-5D severity 
levels for anxiety/depression and usual activities for the acute 
attack. Table 1 shows the patient interpretations of the 0–10 
responses to the question inquiring about the impact of the 
last attack on usual activities, and Table 2 shows the patient 
interpretations of the 0–10 responses to the item inquiring 
about anxiety about having an attack in the future. Based 
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on the interpretations, it was determined that for both usual 
activities and anxiety/depression, the numerical responses 
0–1 would be best assigned to the EQ-5D severity level no 
problems, 2–6 to some or moderate problems, and 7–10 
to extreme problems. With respect to the EQ-5D self-care 
and mobility domains, it was assumed that self-care is 
not impacted during an attack or between attacks and that 
mobility is not impacted between attacks; this is a conserva-
tive approach and an acknowledged potential limitation. Only 
patients who had had an attack within the past 6 months were 
included in the analysis.
Each of the EQ-5D levels has a predetermined utility 
weight based on the time trade-off exercise; the present 
research used UK general population weights, as detailed 
by Dolan.19 Table 3 shows, for both an attack and between 
attacks, how each EQ-5D domain severity level and respective 
UK population disutility weight were linked to the respective 
HAE-BOIS-Europe survey items and responses. These nega-
tive values were added to 1.0 to arrive at an overall EQ-5D 
index score.26 The formula was applied to the respondents 
of the HAE-BOIS-Europe survey on the individual patient 
level. Mean EQ-5D utility scores were calculated for the last 
attack, overall, and by pain severity (no/mild, moderate, and 
severe pain), as well as for between attacks. Country-specific 
utility scores were also computed. As shown in Table 3, to 
assess pain and discomfort during the latest HAE attack 
from the HAE-BOIS survey, patients answered the question 
“what was the worst pain you had during your most recent 
HAE attack?” Possible responses were “no pain”, “mild or 
moderate pain”, or “severe pain”, which very closely matches 
“no pain or discomfort”, “moderate pain or discomfort”, and 
“extreme pain or discomfort” on the EQ-5D pain/discomfort 
domain, and so mapping here involved a direct translation 
of responses. Between attacks, this was interpreted from 
the HAE-BOIS survey question, “In general, how would 
you describe your health?” with the answer of “excellent or 
very good” being translated as “no pain or discomfort” on 
the EQ-5D pain and discomfort domain, “good and fair” to 
indicate “moderate pain or discomfort”, and “poor” to be 
indicative of “extreme pain or discomfort”. An analysis of 
variance test was used to compare differences in utility scores 
across countries as well as across pain severity levels of the 
last attack. SAS® Enterprise Guide® 4.3 (SAS Institute Inc., 
Cary, NC, USA) was used for all analyses.
Results
Overall, a total of 111 HAE-BOIS-Europe survey participants 
completed all of the selected items (41 Spain, 40 Germany, 
30 Denmark; 51% female; average [range] age: 40 [16–81] 
years). The mean EQ-5D utility scores for the last HAE attack 
and for between attacks were 0.444 and 0.722, respectively 
and comparable across countries. Utilities worsened as attack 
pain increased (no/mild pain =0.613; moderate pain =0.467; 
and severe pain =0.080; P0.001; Table 4). For both acute 
attacks and between attacks, the domains with the greatest 
percentages indicating impairment were pain/discomfort and 
anxiety/depression. For pain/discomfort, 90% and 81% of 
patients indicated at least some impairment for acute attacks 
and between attacks, respectively; for anxiety/depression, 
76% and 49% indicated at least some impairment for acute 
attacks and between attacks, respectively. Results were 
consistent across countries.
Discussion
This research presents an approach for estimating EQ-5D util-
ity values during an HAE attack as well as between attacks. 
This approach is sensible based on the reasonable overlap of 
concepts between the respective HAE-BOIS-Europe survey 
items and the EQ-5D. The findings suggest that both during 
and between attacks, HAE causes substantial suffering from 
the patient perspective. This research fills an unmet need in 
the HAE literature, providing preference estimates in HAE, 
based on patient-reported impacts that could be used in future 
cost–utility analyses of HAE therapies.
In HAE, utility values have previously been measured in 
the following ways: clinician report reflecting the clinician’s 
perception of the patient’s experience of a moderate or severe 
attack;27 using the standard gamble approach for HAE health 
states in a general population sample (comparing the health 
states of HAE without any effective emergency medication, 
HAE with effective emergency medication available in a 
hospital, and HAE with effective emergency medication 
available for self-administration);28 and retrospectively in a 
survey in which HAE patients estimated EQ-5D responses 
for the attack-free and acute attack states but did not include 
disease-specific considerations.29 This study has taken 
a different approach by estimating utilities based on HAE 
disease-specific items characterizing the patient’s reported 
disease experience.
Our results show that patients with HAE experience low 
utilities during acute attacks, and this is dependent upon the 
pain severity of the attack. Indeed, we observed statistically 
significant differences between the utility values of different 
attack severities, suggesting that utilities could discriminate 
between mild/moderate and severe attacks. The utility for 
a severe attack was very low, 0.08, indicating substantial 
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Table 3 Mapping of eQ-5D responses to hAe-BOis-europe survey items
EQ-5D 
domain26
EQ-5D description26 EQ-5D 
disutility 
(UK)26
Rating of HAE-BOIS-Europe survey items for EQ-5D utility
During the latest attack Between attacks
Pain/discomfort Question 
on survey
What was the worst pain you had 
during your most recent hAe attack?
in general, how would you 
describe your health?
level 1 no pain or discomfort −0.0 no pain excellent or very good
level 2 Moderate pain or discomfort −0.123 Mild or moderate pain good or fair
level 3 extreme pain or discomfort −0.386 severe pain Poor
Mobility Question 
on survey
how long did the attack stop you 
from performing daily activities?
n/A
level 1 no problems in walking 
about
−0.0 2 h or 2–4 h Assume hAe does not impact 
mobility between attacks 
(ie, eQ-5D disutility =−0.0)
level 2 some problems in walking 
about
−0.069 4–12 h, 12–24 h, or 2 d
level 3 Confined to bed −0.314 3 d, 4 d, or 4 d
self-care Question 
on survey
n/A n/A
level 1 no problems with self-care −0.0 Assume hAe attack does not 
impact self-care (ie, eQ-5D 
disutility =−0.0)
Assume hAe does not impact self-
care between attacks (ie, eQ-5D 
disutility =−0.0)
level 2 some problems washing or 
dressing myself
−0.104
level 3 Unable to wash or dress 
myself
−0.214
Usual activities Question 
on survey
During your most recent attack, 
how much did the hAe attack 
affect your ability to do your 
regular daily activities, other than 
work at a job/be a student?
in the past 6 months, please think 
how much hAe affected your 
ability to do your regular daily 
activities, other than work at a 
job/be a student, between attacks
level 1 no problems with 
performing my usual activities
−0.0 no problems (ie, hAe-BOis-
europe survey patient-rated 
level =0.0–1.0)
no problems (ie, hAe-BOis-
europe survey patient-rated 
level =0.0–1.0)
level 2 some problems with 
performing my usual activities
−0.036 some or moderate levels 
(ie, hAe-BOis-europe survey 
patient-rated level =2.0–6.0)
some or moderate levels 
(ie, hAe-BOis-europe survey 
patient-rated level =2.0–6.0)
level 3 Unable to perform my usual 
activities
−0.094 extreme problems 
(ie, hAe-BOis-europe survey 
patient-rated level =7.0–10.0)
extreme problems 
(ie, hAe-BOis-europe survey 
patient-rated level =7.0–10.0)
Anxiety/depression Question 
on survey
how anxious are you about having 
an hAe attack in the future?
Average of how often did you 
get sudden feelings of panic about 
hAe symptoms/attacks during 
the past 6 months? and how 
distressed are you about your 
hAe attacks/symptoms now? 
(1–5 scale each)
level 1 not anxious or depressed −0.0 no problems (ie, hAe-BOis-
europe survey patient-rated 
level =0.0–1.0)
hAe-BOis-europe survey patient-
rated level 2.5 (1–5 scale)
level 2 Moderately anxious or 
depressed
−0.071 some or moderate levels 
(ie, hAe-BOis-europe survey 
patient-rated level =2.0–6.0)
hAe-BOis-europe survey patient-
rated level =2.5–4.0
level 3 extremely anxious or 
depressed
−0.236 extreme problems 
(ie, hAe-BOis-europe survey 
patient-rated level =7.0–10.0)
hAe-BOis-europe survey patient-
rated level 4.0 (1–5 scale)
Notes: For eQ-5D disutility (UK), the constant term accounted for any dysfunctional state =−0.081, the constant term n3 accounted for if level 3 occurs within at least one 
dimension: −0.269, and full health =1. The summation of eQ-5D disutility (UK) values, including these three terms and eQ-5D disutility values for each eQ-5D domain at one 
of three levels in each domain, gives rise to the estimated value of eQ-5D utility.26
Abbreviations: eQ-5D, euroQol 5-Dimensions; hAe, hereditary angioedema; hAe-BOis-europe, hereditary Angioedema Burden of illness study in europe; h, hours, d, days; 
n/A, not applicable.
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Study limitations include the use of an indirect non-
validated approach for obtaining EQ-5D-based utilities. 
Nevertheless, the use of mapping to predict utility values has 
been broadly used previously37 and the HAE-BOIS-Europe 
survey items selected for the manual crosswalking to the 
EQ-5D appear to be sufficiently comparable conceptually. 
A comparison with utilities derived from the EQ-5D instru-
ment would be a useful area for future study. In addition, it 
was assumed that attacks do not impact self-care and that 
between attacks, there is no impact on self-care or mobility; 
while the results appear sensible and compare realistically 
to other disease states, this approach may underestimate 
patient burden. Nonetheless, utilities were derived based 
on patient-reported responses to disease-specific items; 
this should result in more disease-specific results. Also, 
the results are consistent on several levels: overall mean 
utilities derived from the study approach compare sensibly 
patient burden. In addition, between attacks, utilities do not 
reach UK general population norms (0.72 compared with 
0.86; P0.001).30 In contrast, utilities for the chronic state 
appear to be similar to UK population norms for other epi-
sodic diseases (migraine, epilepsy), suggesting that HAE as 
a condition has further long-term impacts on patients’ lives 
even when they are not having an attack.31,32
In comparison with the published literature reporting utili-
ties for other disease areas, between attacks the mean utility is 
similar (ie, 0.05 difference) to that of partially controlled or 
uncontrolled asthma (0.72)33 and ankylosing spondylitis (0.69; 
Table 5).34 The mean utility of an acute HAE attack (0.44) is 
comparable to that of ischemic heart disease with moderate/
severe angina (0.45)35 or renal failure on hemodialysis (0.44).36 
Furthermore, an EQ-5D value of 0.44 indicates that the general 
population would be willing to trade off 56% of their remain-
ing life to avoid living in that health state.
Table 4 estimated eQ-5D utilities during and between attacks by country
HAE-related 
health state
All Spain Germany Denmark P-valuea
n Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD
Acute hAe state
Overall 111 0.444±0.30 41 0.412±0.30 40 0.514±0.29 30 0.396±0.32 0.184
By pain severity of last attack:*
no pain or mild 41 0.613±0.26 22 0.538±0.28 12 0.672±0.22 7 0.745±0.22
Moderate 48 0.467±0.27 14 0.358±0.25 19 0.606±0.20 15 0.394±0.27
severe 22 0.080±0.08 5 0.006±0.01 9 0.110±0.08 8 0.093±0.09
Between hAe attacks 111 0.722±0.23 41 0.705±0.26 40 0.737±0.19 30 0.728±0.24 0.816
Notes: aAnalysis of variance test. *P0.001 for comparison of differences in utility values by pain severity levels among overall sample.
Abbreviations: eQ-5D, euroQol 5-Dimensions; hAe, hereditary angioedema; sD, standard deviation.
Table 5 eQ-5D utilities reported for selected conditions
Reference/country Condition Utility
stafford et al (2012)/UK31 Migraine: chronic state 0.87
Kind et al (1999)/UK30 UK general population norm 0.86
Westerhuis et al (2011)/the netherlands32 epilepsy 0.80
Dyer et al (2010)/worldwide35 ischemic heart disease with mild angina 0.80
ismail et al (2010)/england38 Type i diabetes mellitus 0.79
Terzano et al (2012)/italy33 Asthma, partially controlled or uncontrolled 0.72
hAe-BOis-europea hAe: chronic (between attacks) 0.72
Mustur et al (2009)/Montenegro34 Ankylosing spondylitis 0.69
Marra et al (2004)/canada39 rheumatoid arthritis 0.66
Pickard et al (2004)/canada40 6 months after stroke 0.62
hAe-BOis-europea hAe: attack with no pain or mild pain 0.61
stafford et al (2012)/UK31 Migraine: moderate severity 0.53
hAe-BOis-europea hAe: attack with moderate pain 0.47
Dyer et al (2010)/worldwide35 ischemic heart disease with moderate/severe angina 0.45
lee et al (2005)/Wales36 renal failure on hemodialysis 0.44
hAe-BOis-europea hAe: acute attack (overall) 0.44
Pickard et al (2004)/canada40 Acute stroke 0.31
hAe-BOis-europea hAe: attack with severe pain 0.08
Note: arefers to current study with data shown in bold. 
Abbreviations: eQ-5D, euroQol 5-Dimensions; hAe, hereditary angioedema; hAe-BOis-europe, hereditary Angioedema Burden of illness study in europe.
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with other disease states for both acute attacks and between 
attacks (Table 5). As expected, as pain severity increased, 
attack utilities declined and were comparable with conditions 
generally considered more severe; these values were consis-
tent across countries. Future research might incorporate this 
methodology, providing additional data that may substantiate 
the validity of our approach.
Conclusion
In summary, acute attacks as well as the chronic experience 
of HAE impair patients’ quality of life to a degree similar 
to that of other serious chronic diseases. This suggests that 
the detrimental effects of HAE as a lifelong disease char-
acterized by acute attacks are meaningful and may cause 
long-lasting lifestyle impairment. This may translate into 
long-term reductions in quality of life. Our findings suggest 
that despite the availability of various treatment options, 
more comprehensive disease management strategies need 
to be considered to minimize the severity, frequency, and 
overall impact of HAE attacks. Utility values can be used to 
help advocate for and raise awareness among policymakers, 
the global community, and the clinical community of the 
burden of HAE and the substantial unmet need for effective 
treatments.
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